Status:
COMPLETED
Understanding Pine Bark Extract as an Alternative Treatment (UPBEAT) Study
Lead Sponsor:
Stanford University
Collaborating Sponsors:
Funded by Toyo Shinyaku Co Ltd
Conditions:
Hypertension
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
The purpose of this study is to investigate the efficacy of Flavangenol® (Toyo Shinyaku, Japan), a pine bark extract, in lowering blood pressure and improving glycemic control and plasma lipoprotein p...
Detailed Description
Cardiovascular disease is the number one cause of death in the Unites States. Our study tests the efficacy of pine bark extract in improving a number of cardiovascular disease risk factors. We are con...
Eligibility Criteria
Inclusion
- Systolic blood pressure between 125 and 159 mmHg and diastolic blood pressure (DBP) \< 100 mmHg
- Body mass index (BMI) 25.0-34.9
- Triglycerides (TG) \< 450 mg/dL
- Low Density Lipoprotein (LDL) \< 200 mg/dL
- Fasting blood glucose (FBG) \< 126 mg/dL
Exclusion
- DBP \> 95 mmHg
- LDL \> 170 mg/dL
- TG \> 300 mg/dL
- FBG \> 110 mg/dL
Key Trial Info
Start Date :
October 1 2006
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
August 1 2008
Estimated Enrollment :
130 Patients enrolled
Trial Details
Trial ID
NCT00425945
Start Date
October 1 2006
End Date
August 1 2008
Last Update
April 2 2014
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Stanford University School of Medicine
Stanford, California, United States, 94305